Modulation of the Immune Microenvironment of High-Risk Ductal Carcinoma In Situ by Intralesional Pembrolizumab Injection

Patients with high-risk DCIS were enrolled in this 3×3 Phase I dose-escalation pilot study of two, four and eight mg intralesional injections of the PD-1 immune checkpoint inhibitor, pembrolizumab.